drugset
drugset / Trial / NCT03279146

A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects

NCT03279146 ↗

Phase 1 Completed 29 enrolled ContraVir Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelOther

Summary

This is a Phase 1 study to evaluate the PK profile of TXL oral formulations in healthy subjects

Timeline

Start
2017-09-06
Primary completion
2018-06-09
Completion
2018-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Exalidex Other / unclassified — Oral

Indications

No indication recorded.